论文部分内容阅读
目的:观察老年直肠癌术前新辅助放化疗的安全性。方法:选择年龄≥65岁直肠癌28例为观察组,<65岁直肠癌28例为对照组。两组术前均行新辅助放化疗,剂量为1.8～2.0 Gy/d,每周5天,共4～5周,累计剂量为45～50 Gy;放化疗期间给予卡培他滨2500 mg/(m2.d),分2次口服,连服2周,休息1周,3周为1个疗程,共2个疗程;比较两组不良反应发生情况。结果:观察组肝功能损害和骨髓抑制不良反应分级病例数与对照组比较,差异显著(P<0.05),不良反应程度也较对照组更加严重,但未发生Ⅳ级不良反应及死亡病例。恶心、呕吐、腹泻、手足综合征、放射性皮炎和放射性直肠炎等不良反应分级病例数,两组差异不显著(P>0.05)。结论:对身体条件允许的老年直肠癌患者,术前行新辅助放化疗是安全和可行的。
Objective: To observe the safety of neoadjuvant radiochemotherapy in senile rectal cancer. Methods: 28 cases of rectal cancer ≥65 years old were selected as the observation group, and 28 cases of rectal cancer <65 years old as the control group. Neoadjuvant radiotherapy and chemotherapy were performed in both groups preoperatively at a dose of 1.8-2.0 Gy / d for 5 days a week for 4-5 weeks with a cumulative dose of 45-50 Gy. Capecitabine 2500 mg / (m2.d), 2 times orally, even for 2 weeks, 1 week rest, 3 weeks for a course of treatment, a total of 2 courses; compare two groups of adverse reactions. Results: There were significant differences between the observation group and the control group (P <0.05). The degree of adverse reactions was more serious than that of the control group, but there were no grade Ⅳ adverse reactions and deaths. Nausea, vomiting, diarrhea, hand-foot syndrome, radiodermatitis and radiological proctitis and other adverse reaction grading cases, the difference between the two groups was not significant (P> 0.05). Conclusion: Neoadjuvant chemoradiation is safe and feasible for preoperative patients with geriatric rectal cancer.